CATABASIS PHARMACEUTICALS INC CATB Cash Flow

Catabasis pharmaceuticals inc (CATB)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15
Operating activities
Net loss
-28,207	-26,293	-25,743	-24,908	-24,256	-25,870	-25,307	-26,645	-27,140	-27,364	0	0	0	-	-	-	-	-	-	-	-
Net loss
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-35,548	-	0	0	0
Reconciliation of net loss to net cash used in operating activities:
Non-cash items
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accretion of discount/premium on investment securities
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Depreciation and amortization
-	-	-	-	-	119	178	244	278	304	332	365	391	395	372	304	242	202	0	0	0
Stock-based compensation expense
-	-	-	-	-	1,771	1,846	1,945	1,981	2,007	2,086	2,081	2,117	2,160	2,090	2,068	1,905	1,658	0	0	0
Accretion of discount/premium on investment securities
-	-	-	-	-	-	-	-	-	-26	-67	-96	-135	-148	0	0	0	-	-	-	-
Non-cash interest expense
-	-	-	-	-	37	65	94	125	155	187	218	248	277	302	323	334	293	0	0	0
Services received in non-monetary exchange
35	33	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in assets and liabilities:
Prepaid expenses and other current assets
974	1,289	728	362	28	177	115	-439	-131	93	180	-20	210	229	360	416	294	450	0	0	0
Other assets
-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Right-of-use asset-operating
-57	-96	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
-760	-211	1,070	904	368	662	-155	-1,684	178	-632	-304	517	-621	77	-245	-243	505	196	0	0	0
Accrued expenses
1,501	-205	-158	-407	-640	396	-45	284	-1,038	-1,215	-737	88	627	418	1,094	343	1,128	954	0	0	0
Deferred rent
-	-	-	-	-	-	-	-	-	6	44	52	65	8	-40	-26	-22	-18	0	0	0
Other liabilities
-	-69	-87	-90	-90	-34	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-26,971	-26,569	-24,068	-23,369	-23,233	-23,465	-23,833	-25,472	-25,550	-26,836	0	0	0	-	-	-	-	-	-	-	-
Investing activities
Purchases of short-term investments
150,959	155,197	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sales and maturities of short-term investments
149,195	151,127	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-31,712	-	0	0	0
Purchases of available-for-sale securities
-	-	-	-	-	-	-	-	-	-	-	-	-	45,539	0	0	0	-	-	-	-
Sales and maturities of available-for-sale securities
-	-	-	-	-	-	-	-	-	-	-	31,863	42,034	30,456	0	0	0	-	-	-	-
Purchases of property and equipment
-	-	-	-	-	-	-	-	-	57	80	110	178	459	797	774	686	421	0	0	0
Net cash used in investing activities
-1,776	-4,082	0	0	0	-	-	-	-	14,883	0	0	0	-	-	-	-	-	-	-	-
Financing activities
Net cash provided by (used in) investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-29,465	-	0	0	0
Proceeds from public offerings, net of issuance costs
24,434	18,505	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of preferred stock, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12,331	0	0	0
Proceeds from at-the-market offering, net of issuance costs
6,076	7,061	3,229	2,255	1,985	8,253	9,439	10,048	14,134	8,036	0	0	0	-	-	-	-	-	-	-	-
Proceeds from exercise of common stock options and warrants
-	-	-	-	-	-	-	-	-	23	0	0	0	-	-	-	-	-	-	-	-
Proceeds from exercise of common stock options and warrants
-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	0	0	-	0	0	0
Proceeds from borrowing
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5,000	0	0	0
Payments on borrowing
-	-	-	-	-	2,848	3,333	3,333	3,333	3,333	3,333	3,334	3,333	3,333	0	0	0	-	-	-	-
Deferred initial public offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Debt issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7	0	0	0
Net cash provided by financing activities
30,561	25,620	21,441	19,195	57,498	44,295	44,995	46,044	10,803	4,726	0	0	0	-	-	-	-	-	-	-	-
Net increase (decrease) in cash, cash equivalents and restricted cash
1,814	-5,031	-2,111	-40,316	-5,378	-1,075	-1,837	20,562	-14,765	-7,227	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by (used in) financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	60,692	-	0	0	0
Net (decrease) increase in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-39,184	-46,245	-57,270	-485	48,112	0	0	0
Supplemental disclosure of cash flow information
Cash paid for interest
-	-	-	-	-	79	137	200	265	327	0	0	0	-	-	-	-	-	-	-	-
Non-cash investing activities:
Fixed asset purchases included in accounts payable
0	-	-	-	-	-	-	-	-	-	-	-	0	-	-	0	0	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	753	-	0	0	0
Non-cash financing activities
Public offering issuance costs included in current liabilities
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrants for the purchase of series B preferred stock issued in conjunction with credit facility
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	107	0	0	0
Public offering issuance costs included in accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-492	0	0	0